SCHEMBL3032020

SCHEMBL3032020

CC(C)(C1CCN(c2cccc3c(OC(=O)C(F)(F)F)nccc23)CC1)S(=O)(=O)c1cccc(C(F)(F)F)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.46
CACNA1B Q00975 3/20 0.46
NR1I2 O75469 1/20 0.46
HSD11B1 P28845 1/20 0.38
CTSS P25774 1/20 0.38
HTR6 P50406 3/20 0.38
LMNA P02545 1/20 0.38
GAA P10253 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.37
POLB P06746 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
DRD2 P14416 1/20 0.37
ADRA1D P25100 1/20 0.37
ADRA1A P35348 1/20 0.37
ADRA1B P35368 1/20 0.37
KDM4E B2RXH2 1/20 0.36
CNR1 P21554 1/20 0.36
RORC P51449 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3132528 0.84 CACNA1B (0.38) CACNA1BHSD11B1CTSSLMNAGAA
Trifluoroacetic Acid SCHEMBL3036303 0.81 CYP3A4 (0.48) CYP3A4CACNA1BNR1I2HSD11B1HTR6
SCHEMBL13221404 0.80 CLK1 (0.50) CYP3A4CACNA1BNR1I2HSD11B1CTSS
SCHEMBL3036305 0.79 CACNA1B (0.46) CYP3A4CACNA1BNR1I2HTR6LMNA
Trifluoroacetic Acid SCHEMBL3032018 0.78 CYP3A4 (0.47) CYP3A4CACNA1BNR1I2KDM4E
SCHEMBL13221408 0.77 CYP3A4 (0.47) CYP3A4CACNA1BNR1I2HSD11B1CTSS
Trifluoroacetic Acid SCHEMBL3035212 0.76 CYP3A4 (0.49) CYP3A4CACNA1BNR1I2HSD11B1CTSS
SCHEMBL8043819 0.75 SLC40A1 (0.49) CYP3A4CACNA1BNR1I2HSD11B1CTSS
SCHEMBL3035214 0.75 CACNA1B (0.47) CYP3A4CACNA1BNR1I2HTR6LMNA
SCHEMBL3031494 0.73 CACNA1B (0.65) CYP3A4CACNA1BNR1I2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2205083-B1 Substituted aryl sulfone derivatives as calcium channel blockers MERCK SHARP & DOHME (US) 2013-07-17 EP claimed
US-20100210620-A1 Substituted Aryl Sulfone Derivatives as Calcium Channel Blockers SCHERING CORPORATION 2010-08-19 US claimed
EP-2205083-B1 Substituted aryl sulfone derivatives as calcium channel blockers MERCK SHARP & DOHME (US) 2013-07-17 EP disclosed
US-20130040932-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS NEUROMED PHARMACEUTICALS LTD. (CA) 2013-02-14 US disclosed
US-8304434-B2 Substituted aryl sulfone derivatives as calcium channel blockers MERCK SHARP & DOHME CORP. (US) 2012-11-06 US disclosed
US-20100210620-A1 Substituted Aryl Sulfone Derivatives as Calcium Channel Blockers SCHERING CORPORATION 2010-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100210620-A1 Substituted Aryl Sulfone Derivatives as Calcium Channel Blockers TRPV1, TRPA1, CACNA1D CYP3A4 939/4885CACNA1B 23/4885NR1I2 765/4885
US-20130040932-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS TRPV1, TRPA1, CACNA1D CYP3A4 939/4885CACNA1B 23/4885NR1I2 765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.